Skip to content

OS Therapies OSTX Income Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$7.35M-16.4%$8.8M+134%$3.76M+50.2%$2.5M+90.9%$1.31M+50.4%
$2.82M-11.7%$3.19M+2.1%$3.12M+33.6%$2.34M-36.6%$3.69M+76.1%
-$10.17M+15.2%-$11.99M-74.3%-$6.88M-42.2%-$4.84M+3.2%-$5M-68.5%
$75.34K
-$228.89K+84.5%-$1.47M-2,266,163%$65-100.0%$302.11K-73.1%$1.12M+4,625%
50%0.0%50%50%0.0%
-$10.4M+22.8%-$13.46M-95.7%-$6.88M-51.6%-$4.54M-17.0%-$3.88M-29.6%
-$0.27+34.1%-$0.41-95.2%-$0.21-10.5%-$0.19-5.6%-$0.18+71.9%
-$10.04M+15.3%-$11.86M-75.6%-$6.75M-42.9%-$4.73M+5.5%-$5M-68.6%
-$10.17M+15.2%-$11.99M-74.3%-$6.88M-42.2%-$4.84M+3.2%-$5M-68.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is OS Therapies profitable?
OS Therapies is not currently profitable: it reported a net loss of $35.3M over the trailing twelve months.
What is OS Therapies's earnings per share?
OS Therapies's diluted EPS over the trailing twelve months is $-1.08.
Where does OS Therapies's income statement data come from?
Every line is extracted from OS Therapies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.